Trevi Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

TRVI$14.91-2.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

Trevi Ther apeutics, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(Amounts in thousands, except share amounts)

Additional · Accumulated Other · Total
Common Stock · Paid- · Comprehensive · Accumulated · Stockholders’
	Shares	Amount	in Capital	Loss	Deficit	Equity
Balance at March 31, 2024	68,960,167	$69	$322,368	$(67)	$(250,036)	$72,334
Stock-based compensation	—	—	1,127	—	—	1,127
Issuance of common stock from exercise of stock options	126,887	—	214	—	—	214
Issuance of common stock under the at-the-market sales agreement, net of commissions and allocated fees	1,474,926	2	4,832	—	—	4,834
Issuance of common stock from Employee Stock Purchase Plan	30,675	—	34	—	—	34
Issuance of common stock from pre-funded warrant exercise	1,999,262	2	(2)	—	—	—
Unrealized losses on available-for-sale marketable securities	—	—	—	(17)	—	(17)
Net loss	—	—	—	—	(12,352)	(12,352)
Balance at June 30, 2024	72,591,917	$73	$328,573	$(84)	$(262,388)	$66,174
Balance at March 31, 2023	60,065,408	$60	$318,230	$(88)	$(216,470)	$101,732
Stock-based compensation	—	—	606	—	—	606
Issuance of common stock from exercise of stock options	14,936	—	7	—	—	7
Issuance of common stock from Employee Stock Purchase Plan	19,273	—	33	—	—	33
Issuance of common stock from pre-funded warrant exercise	2,998,838	3	(3)	—	—	—
Unrealized losses on available-for-sale marketable securities	—	—	—	(160)	—	(160)
Net loss	—	—	—	—	(7,145)	(7,145)
Balance at June 30, 2023	63,098,455	$63	$318,873	$(248)	$(223,615)	$95,073

Additional · Accumulated Other · Total
Common Stock · Paid- · Comprehensive · Accumulated · Stockholders’
	Shares	Amount	in Capital	Loss	Deficit	Equity
Balance at December 31, 2023	68,283,699	$68	$321,642	$(29)	$(239,134)	$82,547
Stock-based compensation	—	—	1,850	—	—	1,850
Issuance of common stock from exercise of stock options	129,518	—	218	—	—	218
Issuance of common stock under the at-the-market sales agreement, net of commissions and allocated fees	1,474,926	2	4,832	—	—	4,834
Issuance of common stock from Employee Stock Purchase Plan	30,675	—	34	—	—	34
Issuance of common stock from pre-funded warrant exercise	2,673,099	3	(3)	—	—	—
Unrealized losses on available-for-sale marketable securities	—	—	—	(55)	—	(55)
Net loss	—	—	—	—	(23,254)	(23,254)
Balance at June 30, 2024	72,591,917	$73	$328,573	$(84)	$(262,388)	$66,174
Balance at December 31, 2022	59,943,430	$60	$317,590	$(122)	$(210,069)	$107,459
Stock-based compensation	—	—	1,183	—	—	1,183
Issuance of common stock from exercise of stock options	136,914	—	70	—	—	70
Issuance of common stock from Employee Stock Purchase Plan	19,273	—	33	—	—	33
Issuance of common stock from pre-funded warrant exercise	2,998,838	3	(3)	—	—	—
Unrealized losses on available-for-sale marketable securities	—	—	—	(126)	—	(126)
Net loss	—	—	—	—	(13,546)	(13,546)
Balance at June 30, 2023	63,098,455	$63	$318,873	$(248)	$(223,615)	95,073

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.